VYNE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	15 849.00
平均成交量	106 139
市值	35.25M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $-0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.920
ATR14	$0.0240 (0.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Zeronda Tyler	Sell	94	Common Stock
2024-04-01	Stuart Iain	Sell	157	Common Stock
2024-04-01	Harsch Mutya	Sell	161	Common Stock
2024-04-01	Domzalski David	Sell	1 004	Common Stock
2024-01-01	Zeronda Tyler	Buy	62 500	Common Stock

INSIDER POWER
-56.80
Last 99 transactions
Buy: 3 356 313 \| Sell: 7 897 303

音量相关性

長: 0.36 (neutral)

短: -0.34 (neutral)

Signal:(51.533) Neutral

VYNE Therapeutics Inc. 相关性

10 最正相关
ALBO	0.962
CMPI	0.962
OCSL	0.934
PALT	0.913
IRMD	0.911
PLRX	0.91
MLAC	0.905
ANDE	0.905
NATI	0.903
DRNA	0.902

10 最负相关
CFV	-0.951
AKAM	-0.888
BNIXU	-0.882
GMII	-0.88
TUEM	-0.874
EAR	-0.85
SHLD	-0.845
TRMK	-0.84
DTSS	-0.838
VIVE	-0.837

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

VYNE Therapeutics Inc. 相关性 - 货币/商品

0.49
( neutral )

0.50
( neutral )

0.00
( neutral )

0.37
( neutral )

-0.29
( neutral )

0.17
( neutral )

VYNE Therapeutics Inc. 财务报表

Annual	2023
营收:	$424 000
毛利润:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2023
营收:	$424 000
毛利润:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2022
营收:	$477 000
毛利润:	$477 000 (100.00 %)
EPS:	$-10.65

FY	2021
营收:	$14.76M
毛利润:	$11.41M (77.31 %)
EPS:	$-1.420

Financial Reports:

No articles found.

VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.